3 research outputs found
Recommended from our members
The Annuli
No full textThe Annuli is a dystopian fiction novel set in post-war U.S.A. that follows Amayas Kalar, a young man from the dejected crater communities, as he traverses his new life on the surface and a competition for prestige that will make him question everything he knows to be true. This thesis contains the first of the novel’s three acts, which primarily focuses on constructing the dystopic world of Valos, developing its main characters, and bringing Amayas towards the rising action and his entrance into the Annuli.
Accompanying the first act of this novel is a short treatise, brought to life through the conceit of vignettes, each of which is a letter written from our main character, Amayas, to his dead best friend, Jakos, during his exploration of the unrevitalized wasteland of the 5th ring. The treatise hopes to not only humanify Amayas for readers who may view main characters as exceptionally extraordinary and incapable of mundanity, but also to continue building out the greater story and its relationships while elaborating on and critiquing a number of choices made by the author within the larger text.Plan II Honors Progra
Protocol for a phase 3, randomised, active-control study of four-factor prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgery patients requiring coagulation factor replacement: the LEX-211 (FARES-II) trial
No full textIntroduction Reduced thrombin generation is an important component of post cardiopulmonary bypass (CPB) coagulopathy. To replenish coagulation factors and enhance thrombin generation in bleeding surgical patients, frozen plasma (FP) and four-factor prothrombin complex concentrate (4F-PCC) are used. However, the efficacy–safety balance of 4F-PCC relative to FP in cardiac surgery is unconfirmed.Methods and analysis LEX-211 (FARES-II) is an active-control, randomised, phase 3 study comparing two coagulation factor replacement therapies in bleeding adult cardiac surgical patients at 12 hospitals in Canada and the USA. The primary objective is to determine whether 4F-PCC (Octaplex/Balfaxar, Octapharma) is clinically non-inferior to FP for haemostatic effectiveness. Inclusion criteria are any index (elective or non-elective) cardiac surgery employing CPB and coagulation factor replacement with 4F-PCC or FP ordered in the operating room for bleeding management. Patients will be randomised to receive 1500 or 2000 international units of 4F-PCC or 3 or 4 units of FP, depending on body weight. The primary endpoint of haemostatic treatment response is ‘effective’ if no additional haemostatic intervention is required from 60 min to 24 hours after the first initiation of 4F-PCC or FP; or ‘ineffective’ if any other haemostatic intervention (including a second dose of study drug) is required. An estimated 410 evaluable patients will be required to demonstrate non-inferiority (one-sided α of 0.025, power ≥90%, non-inferiority margin 0.10). Secondary outcomes include transfusions, bleeding-related clinical endpoints, coagulation parameters and safety.Ethics and dissemination The trial has been approved by the institutional review boards of all participating centres. Trial completion is anticipated at the end of 2024, and results will be disseminated via publications in peer-reviewed journals and conference presentations in 2025. The results will advance our understanding of coagulation management in bleeding surgical patients, potentially reducing the need for allogeneic blood products and improving outcomes in surgical patients.Trial registration number NCT05523297
Trees, Shrubs and Grasses for Saltlands: an Annotated Bibliography
No full textResource /Energy Economics and Policy,
